Bioxcel Therapeutics, INC 8-K filings

BioXcel Therapeutics reports Q1 2025 financial results, highlighted by the completion of enrollment in the SERENITY At-Home Phase 3 trial for acute agitation treatment.

BioXcel Therapeutics has entered into an agreement with Canaccord Genuity to sell up to $8.135 million of its common stock through an at-the-market equity offering.

BioXcel Therapeutics announces its Q4 and full year 2024 financial results, highlighting progress in the SERENITY At-Home Phase 3 trial and a strengthened cash position.

BioXcel Therapeutics receives notification from Nasdaq regarding potential delisting due to failure to meet the minimum market value of listed securities requirement.

BioXcel Therapeutics announces that its SERENITY At-Home Phase 3 trial for BXCL501 has reached 50% enrollment as of March 20, 2025, with topline data expected in the second half of 2025.

BioXcel Therapeutics enters into a securities purchase agreement for a registered direct offering of common stock and warrants, aiming to raise $14 million.

BioXcel Therapeutics reports the closure of an FDA inspection with Voluntary Action Indicated status, progress in its SERENITY At-Home Phase 3 trial, regaining Nasdaq compliance, and the resignation of its Chief of Product Development and Medical Officer.

BioXcel Therapeutics implements a 1-for-16 reverse stock split to be effective February 7, 2025, aiming to increase its stock price and maintain its Nasdaq listing.

BioXcel Therapeutics' stockholders approved a reverse stock split at a special meeting held on January 28, 2025.

BioXcel Therapeutics has increased its board size and appointed Dr. Rajiv Patni as a new director, effective January 15, 2025.

BioXcel Therapeutics has amended employment agreements with its CEO, CFO, and CSO, reducing their 2025 base salaries and granting them stock options.

BioXcel Therapeutics has secured approximately $6.2 million through a public offering of common stock and warrants to support its clinical trials and general operations.

BioXcel Therapeutics has entered into a fifth amendment to its credit agreement, securing waivers on certain covenants and establishing new capital raising requirements.

BioXcel Therapeutics announced its third quarter 2024 financial results, highlighting progress in clinical trials for BXCL501 and a decrease in operating expenses.

BioXcel Therapeutics has announced the departure of its Chief Commercial Officer, Matthew Wiley, effective October 2, 2024, and has entered into a consulting agreement with him through his company, Commercial Science, LLC.

BioXcel Therapeutics has received notices from Nasdaq regarding non-compliance with minimum share price and market value requirements, placing its listing status at risk.

BioXcel Therapeutics is reducing its workforce by 28% to prioritize the clinical development of BXCL501 and extend its cash runway.

BioXcel Therapeutics has submitted a proposed protocol to the FDA for a Phase 3 trial of BXCL501 to treat agitation in Alzheimer's dementia patients.

BioXcel Therapeutics has begun enrolling patients in its pivotal Phase 3 SERENITY At-Home trial to assess the safety of BXCL501 for treating agitation associated with bipolar disorders or schizophrenia in an at-home setting.

BioXcel Therapeutics announced a 141% year-over-year increase in IGALMI revenue for Q2 2024, alongside progress in clinical trials for BXCL501.

BioXcel Therapeutics has amended its supply agreement with ARx, LLC, reducing minimum annual payments over the next three years and tying future payments to FDA approvals.

BioXcel Therapeutics announced a 90% increase in quarterly revenue for IGALMI, reaching approximately $1.1 million in the second quarter of 2024.

BioXcel Therapeutics reported positive topline results from a post-marketing study of IGALMI, showing it was well-tolerated and effective in treating agitation episodes in adults with bipolar disorder or schizophrenia.

BioXcel Therapeutics' stockholders approved an amendment to increase the number of authorized common shares from 100 million to 200 million at their 2024 annual meeting.

BioXcel Therapeutics announced a 182% year-over-year increase in IGALMI revenue for Q1 2024, alongside progress in clinical trials and patent portfolio expansion.

BioXcel Therapeutics has announced updates to its clinical development programs, including the design of a Phase 3 trial for BXCL501 in treating agitation at home.

BioXcel Therapeutics has detailed the design of its upcoming Phase 3 TRANQUILITY In-Care trial to evaluate BXCL501 for treating agitation in Alzheimer's dementia patients.

BioXcel Therapeutics has entered into a securities purchase agreement for a registered direct offering to raise approximately $25 million.

BioXcel Therapeutics announced its 2023 financial results and provided updates on its late-stage clinical programs for BXCL501, including plans to generate additional efficacy data for Alzheimer's agitation.

BioXcel Therapeutics is focusing on expanding its neuroscience pipeline, particularly with at-home treatments for agitation, and exploring strategic options for its immuno-oncology assets.